Research on the selection of therapy for Parkinson’s disease

Jiazheng Wang

doi:10.1117/12.2669002

24 March 2023 Research on the selection of therapy for Parkinson’s disease

Jiazheng Wang

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126112A (2023) https://doi.org/10.1117/12.2669002
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Parkinson disease(PD), whose another name is paralysis agitans, has become one of the most common movement disorder disease in China. For Chinese doctor, the levodopa is their first choice to cure PD, but the side-effect is serious for the people who have eaten levodopa for long time. This essay concentrates on how to choose a treatment for PD patients. The method of researching is collecting large number of essays in journals and make some conclusions for diverse medicine and treatments. In conclusion, the levodopa is still the primary choice for PD patients, however, the effect of other therapies also attracts attention.

Citation Download Citation

Jiazheng Wang "Research on the selection of therapy for Parkinson’s disease", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126112A (24 March 2023); https://doi.org/10.1117/12.2669002

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available